PR Newswire (Thu, 5:00PM)
Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
516 people get NBIX articles and Market Currents by email alert.
Get email alerts on NBIX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Apr 24, 2013)
-
-
-
PR Newswire (Mar 27, 2013)
-
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 8, 2013)
-
PR Newswire (Feb 6, 2013)
-
-
-
-
-
Neurocrine's VMAT-2 Enters Phase IIbJason Napodano • Tue, Oct 2, 2012
-
-
-
Neurocrine Could Be A Major Biotech Comeback StoryStephen Simpson • Mon, Mar 19, 2012
-
-
-
-
-
-
-
-
Neurocrine Biosciences: Lessons From Its Collapse (NBIX)Roger Nusbaum • Wed, May 17, 2006
-
-
-
-
-
-
-
3 Small Cap Stocks With Growth On The Horizon That Are Churning Out ProfitsZetaKap • Tue, Aug 21, 2012
-
-
-
-
-
-
-
Tuesday Options RecapFrederic Ruffy • Tue, Mar 27, 2012 -
-
-
-
Insiders Love These 18 High Growth StocksKapitall • Wed, Jan 18, 2012
-
-
15 Small Cap Stocks With High Cash Relative To ExpensesKapitall • Wed, Jan 4, 2012
-
Neurocrine CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
PR Newswire (Thu, 5:00PM)
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Apr 24, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Mar 27, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 8, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Nov 27, 2012)
-
PR Newswire (Nov 20, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 31, 2012)
-
PR Newswire (Oct 24, 2012)
-
at CNBC.com (Oct 3, 2012)
NBIX vs. ETF Alternatives
Company Description
Currently, there's no company description for NBIX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 2, 4:20 PM Neurocrine Biosci (NBIX): Q1 EPS of -$0.18 in-line. Revenue of $0.7M misses by $0.42M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 2, 12:10 AM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
- Wednesday, May 1, 5:35 PM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
- Wednesday, March 27, 1:47 PM Neurocrine Biosciences (NBIX +22%) gains after announcing earlier that its initiated Phase IIb clinical trials to evaluate Elagolix for the treatment of uterine fibroids. Elagolix is an oral gonadotropin-releasing hormone antagonist currently in collaborative development by its partner AbbVie (ABBV -0.4%). Comment! [Healthcare, On the Move]
- Friday, February 8, 7:18 AM Neurocrine Biosciences (NBIX): Q4 EPS of $0.14 beats by $0.22. Revenue of $21.9M (+97.3% Y/Y) beats by $12M. (PR) Comment! [Earnings, Healthcare]
- Friday, February 8, 12:05 AM Notable earnings before Friday’s open: AOL, AXL, BPL, CBOE, ETR, GSM, LH, LPX, MCO, NBIX, PSEC, YRCW Comment! [Earnings]
- Thursday, February 7, 5:30 PM Notable earnings before Friday’s open: AOL, AXL, BPL, CBOE, ETR, GSM, LH, LPX, MCO, NBIX, PSEC, YRCW Comment! [Earnings]
- Wednesday, January 23, 5:05 PM Neurocrine Biosciences, Inc. (NBIX) says its been granted two additional patents related to the company's proprietary Vesicular Monoamine Transporter 2 inhibitor NBI-98854, one by the European Patent Office and one by the USPTO. The European patent is a composition of matter patent that covers chemical compositions, pharmaceutical compositions and uses of various compounds, while the second U.S. patent includes methods of treating hyperkinetic movement disorders. Comment! [Healthcare]
-
Wednesday, December 26, 2012, 5:57 PM
After-hours top gainers, as of 5:30 p.m.: MACK +5%. CLDX +4%. FOLD +4%. IDIX +3%. NBIX +2%.
After-hours top losers: AMBA -2%. DGAZ -2%. MRVL -2%. DNDN -2%. PRSS -1%. 1 Comment [On the Move] - Wednesday, October 31, 2012, 4:21 PM Neurocrine Biosciences (NBIX): Q3 EPS of -$0.05 misses by $0.01. Revenue of $9.4M misses by $0.8M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 31, 2012, 12:10 AM Notable earnings after Wednesday’s close: ALL, BBG, BMC, CCJ, CJES, CRUS, DRE, EEP, ELLI, FSLR, GGP, GNK, HTZ, KEG, MDU, MET, MRGE, MUR, NBIX, PSE, PVA, PXD, RGR, SM, SU, UNM, V, WES Comment! [Earnings]
- Tuesday, October 30, 2012, 5:35 PM Notable earnings after Wednesday’s close: ALL, BBG, BMC, CCJ, CJES, CRUS, DRE, EEP, ELLI, FSLR, GGP, GNK, HTZ, KEG, MDU, MET, MRGE, MUR, NBIX, PSE, PVA, PXD, RGR, SM, SU, UNM, V, WES Comment! [Earnings]
- Monday, October 1, 2012, 4:22 PM Neurocrine Biosciences (NBIX) says it's initiated Phase IIb clinical trials of NBI-98854, its proprietary Vesicular Mono-Amine Transporter 2 compound for the treatment of severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. Topline data on the study is expected in 2Q13. Comment! [Healthcare]
- Tuesday, July 31, 2012, 7:29 PM Neurocrine Biosciences (NBIX): Q2 EPS of -$0.01 beats by $0.02. Revenue of $10.6M (-13% Y/Y) misses by $0.4M. (PR) Comment! [Earnings]
- Wednesday, June 20, 2012, 10:45 AM Neurocrine Biosciences (NBIX +2%) gets a lift after being initiated with a Buy at Roth Capital with a price target of $14. Comment! [Healthcare, Top Stories]
- Tuesday, June 5, 2012, 10:23 AM Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR) Comment! [Healthcare]
-
Codespeed
$NBIX $NPSP technical charts, strong catalysts, good returns: http://seekingalpha.com/a/syx1 - View all 0 replies
-
- View all 0 replies
-
ZetaKap
3 Small Cap Stocks With Growth On The Horizon That Are Churning Out Profits http://bit.ly/NeTLoX $GMK $KKD $NBIX @ZetaKap - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
MagicDiligence
Neurocrine Biosciences $NBIX in the MFI screen today. Small drug developer. Looks like a one-time revenue case, not certain though. - View all 0 replies
-
- View all 0 replies
-
MagicDiligence
Second is $NBIX Neurocrine Biosciences. Small bio-tech, consistent revenue over last 5 quarters, needs a closer look though. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES